29th Jan 2024 17:56
MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Announces departure of Cenk Sumen as chief scientific officer, but he will remain on advisory board.
Current stock price: 397.50 pence, flat
12-month change: down 14%
By Greg Rosenvinge, Alliance News senior reporter
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Related Shares:
MaxCyte